Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Showing 1-25 of 33 citing articles:

An update on peptide-based therapies for type 2 diabetes and obesity
Clifford J. Bailey, Peter R. Flatt, J. Michael Conlon
Peptides (2023) Vol. 161, pp. 170939-170939
Open Access | Times Cited: 70
GIPR/GLP-1R dual agonist therapies for diabetes and weight loss—chemistry, physiology, and clinical applications
Jonathan E. Campbell, Timo D. Müller, Brian Finan, et al.
Cell Metabolism (2023) Vol. 35, Iss. 9, pp. 1519-1529
Open Access | Times Cited: 57
Safety and efficacy of a GLP-1 and glucagon receptor dual agonist mazdutide (IBI362) 9 mg and 10 mg in Chinese adults with overweight or obesity: A randomised, placebo-controlled, multiple-ascending-dose phase 1b trial
Linong Ji, Leili Gao, Hongwei� Jiang, et al.
EClinicalMedicine (2022) Vol. 54, pp. 101691-101691
Open Access | Times Cited: 47
The molecular pharmacology of glucagon agonists in diabetes and obesity
Aaron Novikoff, Timo D. Müller
Peptides (2023) Vol. 165, pp. 171003-171003
Open Access | Times Cited: 40
Obesity and Type 2 Diabetes: Adiposopathy as a Triggering Factor and Therapeutic Options
Angelica Artasensi, Angelica Mazzolari, Alessandro Pedretti, et al.
Molecules (2023) Vol. 28, Iss. 7, pp. 3094-3094
Open Access | Times Cited: 36
Efficacy and Safety of Mazdutide in Chinese Patients With Type 2 Diabetes: A Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial
Bo Zhang, Zhifeng Cheng, Ji Chen, et al.
Diabetes Care (2023) Vol. 47, Iss. 1, pp. 160-168
Open Access | Times Cited: 22
Role of lifestyle and glucagon‐like peptide‐1 receptor agonists for weight loss in obesity, type 2 diabetes and steatotic liver diseases
Anna Giannakogeorgou, Michael Roden
Alimentary Pharmacology & Therapeutics (2024) Vol. 59, Iss. S1
Open Access | Times Cited: 11
Glucagon-like peptide-1 analogs: Miracle drugs are blooming?
Binbin Gong, Zhihong Yao, Chenxu Zhou, et al.
European Journal of Medicinal Chemistry (2024) Vol. 269, pp. 116342-116342
Closed Access | Times Cited: 8
GLP-1R Signaling and Functional Molecules in Incretin Therapy
Wenwei Wan, Qikai Qin, Linshan Xie, et al.
Molecules (2023) Vol. 28, Iss. 2, pp. 751-751
Open Access | Times Cited: 21
Efficacy and safety of Mazdutide on weight loss among diabetic and non-diabetic patients: a systematic review and meta-analysis of randomized controlled trials
David Lubasi Nalisa, Nelson Cuboia, Eman Dyab, et al.
Frontiers in Endocrinology (2024) Vol. 15
Open Access | Times Cited: 6
Glucagon agonism in the treatment of metabolic diseases including type 2 diabetes mellitus and obesity
Jonathan Brix Winther, Jens J. Holst
Diabetes Obesity and Metabolism (2024)
Open Access | Times Cited: 6
Newer pharmacological interventions directed at gut hormones for obesity
Michael Camilleri, Andrés Acosta
British Journal of Pharmacology (2023) Vol. 181, Iss. 8, pp. 1153-1164
Closed Access | Times Cited: 13
G protein-coupled receptors driven intestinal glucagon-like peptide-1 reprogramming for obesity: Hope or hype?
Mohan Patil, Ilaria Casari, Leon N. Warne, et al.
Biomedicine & Pharmacotherapy (2024) Vol. 172, pp. 116245-116245
Open Access | Times Cited: 5
Comparative efficacy of incretin drugs on glycemic control, body weight, and blood pressure in adults with overweight or obesity and with/without type 2 diabetes: a systematic review and network meta-analysis
Song Liu, Jiaqiang Hu, Chen Zhao, et al.
Frontiers in Endocrinology (2025) Vol. 16
Open Access
Gelatin-Coated Copper-Based Metal–Organic Framework for Controlled Insulin Delivery: Possibility toward Oral Delivery System
Pawan Kumar, Navpreet Kaur, Pranav Tiwari, et al.
ACS Materials Letters (2023) Vol. 5, Iss. 4, pp. 1100-1108
Closed Access | Times Cited: 12
Safety and efficacy of GLP-1 and glucagon receptor dual agonist for the treatment of type 2 diabetes and obesity: a systematic review and meta-analysis of randomized controlled trials
Bixin Deng, Tiechao Ruan, Wenting Lu, et al.
Endocrine (2024) Vol. 86, Iss. 1, pp. 15-27
Closed Access | Times Cited: 4
Metabolic diseases in the East Asian populations
Zhonghan Sun, Yan Zheng
Nature Reviews Gastroenterology & Hepatology (2025)
Closed Access
Emerging roles of oxyntomodulin-based glucagon-like peptide-1/glucagon co-agonist analogs in diabetes and obesity
Zhihong Yao, Wang Chen, Zhu Qianqian, et al.
Peptides (2023) Vol. 162, pp. 170955-170955
Closed Access | Times Cited: 10
An updated patent review of GLP-1 receptor agonists (2020-present)
Weiwen Lu, Zhongbo Zhou, Neng Jiang, et al.
Expert Opinion on Therapeutic Patents (2023) Vol. 33, Iss. 9, pp. 597-612
Closed Access | Times Cited: 9
Adaptive infusion of a glucagon‐like peptide‐1/glucagon receptor co‐agonist G3215, in adults with overweight or obesity: Results from a phase 1 randomized clinical trial
David C. D. Hope, Saleem Ansari, Sirazum Choudhury, et al.
Diabetes Obesity and Metabolism (2024) Vol. 26, Iss. 4, pp. 1479-1491
Open Access | Times Cited: 3
The role of incretin receptor agonists in the treatment of obesity
Thomas Först, Christophe De Block, Stefano Del Prato, et al.
Diabetes Obesity and Metabolism (2024) Vol. 26, Iss. 10, pp. 4178-4196
Open Access | Times Cited: 3
Advances in obesity pharmacotherapy; learning from metabolic surgery and beyond
Dimitrios Tsilingiris, Alexander Kokkinos
Metabolism (2023) Vol. 151, pp. 155741-155741
Closed Access | Times Cited: 7
Glucagon-based therapy for people with diabetes and obesity: What is the sweet spot?
Emma Rose McGlone, Tricia Tan
Peptides (2024) Vol. 176, pp. 171219-171219
Open Access | Times Cited: 2
Poly-Agonist Pharmacotherapies for Metabolic Diseases: Hopes and New Challenges
C. Allard, Daniela Cota, Carmelo Quarta
Drugs (2023) Vol. 84, Iss. 2, pp. 127-148
Closed Access | Times Cited: 6
Cautious Optimism Warranted for Stem Cell-Derived Islet Transplantation in Type 2 Diabetes
Hanne Scholz, Valeria Sordi, Lorenzo Piemonti
Transplant International (2024) Vol. 37
Open Access | Times Cited: 2
Page 1 - Next Page

Scroll to top